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Objectives: The use of heparin-coated circuits for cardiopulmonary bypass
attenuates the postperfusion inflammatory response. Postoperative bleeding
and the need for allogeneic blood transfusions are reduced, particularly in
combination with lowered systemic anticoagulation. The two most com-
monly used heparin-coated systems are the Carmeda BioActive Surface
(Medtronic Inc, Minneapolis, Minn) and the Duraflo II coating (Baxter
Healthcare Corp, Bentley Laboratories Division, Irvine, Calif). The 2 sur-
faces are technically unequal, and previous experimental studies have
demonstrated disparities in effects on the immune system and the blood
cells. However, no larger comparative studies of relevant clinical end points
have thus far been reported.
Methods: Over a 24-month period, all patients undergoing coronary artery
bypass were prospectively randomized to one of the two heparin-coated cir-
cuits. Altogether, 1336 consecutive patients were included. The heparin dose
was reduced in all cases, with an activated coagulation time of more than 250
seconds. Clinical data were consecutively collected and stored on a comput-
er for comparative analyses.
Results: There were no statistically significant differences in any demo-
graphic or operative parameters. The Duraflo II patients required less
heparin to keep the target-activated clotting time, confirming the previous
finding of some leakage of heparin from the surface to the circulation.
Otherwise, there were no significant differences in time for ventilatory sup-
port (Duraflo II, 1.7 ± 1.3 hours; Carmeda BioActive Surface, 1.6 ± 1.0
hours; P = .37), amount of postoperative mediastinal drainage (Duraflo II,
665 ± 257 mL; Carmeda BioActive Surface, 688 ± 243 mL; P = .07), need
for allogeneic blood-plasma transfusions (Duraflo II, 4.2% of the patients;
Carmeda BioActive Surface, 4.4% of the patients; P = .93), or hemoglobin
concentration at hospital discharge (Duraflo II, 120 ± 13 g/L; Carmeda
BioActive Surface, 119 ± 13 g/L; P = .08). The effects on renal function and
platelets were similar, as were the incidences of perioperative myocardial
infarction (Duraflo II, 1.5%; Carmeda BioActive Surface, 1.5%; P = .96),
stroke (Duraflo II, 1.3%; Carmeda BioActive Surface, 1.2%; P = .47), and
hospital mortality (Duraflo II, 1 [0.14%] patient; Carmeda BioActive
Surface, 3 [0.45%] patients; P = .31).
Conclusions: Despite differences in technology, complexity, and effects on
biologic markers, no clinical differences were observed between the
Carmeda BioActive Surface system and the Duraflo II coating after coronary
artery bypass operations. The overall clinical results were favorable in both
groups, confirming the safety and feasibility of routine use of heparin-coat-
ed circuits in combination with reduced systemic anticoagulation. 
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Implementation of heparin-coated cardiopulmonarybypass (CPB) circuits in cardiac operations has proved
to attenuate the activation of biologic cascades1-4 and is
assumed to reduce the risk of postperfusion injury.5,6
The presence of thromboresistant heparinized surfaces
has further allowed lower doses of systemic heparin,
with a subsequent reduced need for protamine. This
option has been shown to decrease postoperative bleed-
ing and requirements for bank blood transfusions and
has led to reduced postoperative morbidity.7-10
Among a variety of biologically modified sur-
faces,11 2 separate processes for coating of extracor-
poreal circuits with immobilized heparin have been
available for routine clinical use for many years. The
Carmeda BioActive Surface (CBAS) (Medtronic Inc,
Minneapolis, Minn) involves deposition of a polymer
coating, polyethylenimine, onto various types of sur-
faces. Heparin fragments, prepared from the degrada-
tion of heparin in nitrous acid, are then end point
attached and covalently bonded to the polymer.12 The
Duraflo II (Baxter Healthcare Corp, Bentley
Laboratories Division, Irvine, Calif) process is based
on the concept of modifying the physiochemical prop-
erties of unfractionated heparin with a proprietary
binding agent that has high affinity to a variety of syn-
thetic surfaces.13 In general, the CBAS appears more
complex, but also more stable, than the Duraflo II
coating.14 Reduced complement and granulocyte acti-
vation has been demonstrated individually for both
systems, and in some comparative studies, these
effects were more pronounced for the CBAS than for
the Duraflo II surface.14,15 Also, the release of
endothelin 1 was more reduced with the CBAS equip-
ment than with the Duraflo II.16 However, no studies
of larger patient series have been reported, evaluating
possible differences in clinical outcome variables with
the 2 heparinized systems.
The purpose of this study was to accumulate infor-
mation in a prospectively randomized fashion, focusing
on the most relevant perioperative and postoperative
variables in patients undergoing coronary artery bypass
operations.
Patients and methods
Patients. From January 1998 through December 1999,
1336 consecutive patients underwent myocardial revascular-
ization with the heart-lung machine in our department. All
patients admitted for coronary bypass operations, regardless
of operative risk profile, were included in the study. Because
the use of heparin-coated circuits with reduced anticoagula-
tion is routine in our institution, no informed consent was
obtained from the patients. The majority of the patients
underwent their operations on an elective basis (9.1% were
emergency cases), and 30 (2.2%) patients had their second
revascularization. No patients were receiving mechanical
pump support preoperatively. The patient material is some-
what selected because of the close collaboration with a neigh-
boring university department, in which patients with severe
renal dysfunction, patients with ventricular aneurysms,
patients in need of a combined carotid and coronary opera-
tion, and patients undergoing acute operations after failed
angioplasties are cared for. Otherwise, a typical coronary
artery bypass patient population was treated (Table I).
Randomization and operation. Two identical operating
rooms (ORs) were available, and one of the two heparin-coat-
ed CPB systems was used in each room. All patients were
randomly allocated to one of the ORs, as were the surgeons,
anesthetists, perfusionists, and nurses. More than 75% of the
patients were operated on by one of two surgeons (E.Ø.,
G.T.). The setups of CPB equipment were switched from one
OR to the other every 6 months to avoid any possible selec-
tion bias.
The anesthesia protocol was designed to permit early post-
operative extubation and included mainly a combination of
diazepam (0-0.2 mg/kg), midazolam hydrochloride (0-0.2
mg/kg), fentanyl (4-8 µg/kg), and pancuronium bromide sup-
plemented with isoflurane and nitrous oxide.
At least one internal thoracic artery anastomosis was con-
structed in all but 9 patients (99.3%), supplemented with
saphenous vein grafts. The aorta was crossclamped during
performance of the distal anastomoses. Myocardial protec-
tion consisted of intermittent antegrade administration of
cold blood cardioplegic solution or crystalloid cardioplegic
solution (St Thomas’ Hospital solution No. 2). Blood cardio-
plegia was restricted to high-risk patients, who were defined
as having the following characteristics: (1) age greater than
70 years; (2) insulin-dependent diabetes; (3) unstable angina;
(4) left ventricular ejection fraction of less than 0.5; and (5)
emergency operation.
The proximal anastomoses were performed during partial
occlusion of the ascending aorta while the patient was being
rewarmed. The blood conservation protocol of the institution,
previously described in detail,17 was applied to all patients. The
protocol includes autologous blood removal before CPB with
later retransfusion, returning of all contents of the extracorpo-
real circuit to the patient, and autotransfusion of the shed medi-
astinal blood until 18 hours after the operation. Antifibrinolytic
therapy or anti-inflammatory drugs were not given to any
patients. The amount of postoperative bleeding from the time
of sternal closure until the drains were removed was recorded.
Normovolemic anemia was accepted to a hematocrit level of
0.25 postoperatively; a level below this was considered an indi-
cation for allogeneic red blood cell transfusion. The hemoglo-
bin concentration, as well as platelet counts, were determined
preoperatively, at 3 and 18 hours postoperatively, and at dis-
charge on the fifth to seventh day. Kidney function was moni-
tored by repeated measurements of the serum creatinine level
before and after the operation.
CPB and anticoagulation. Every part of the circuit was
coated with heparin (tip-to-tip), including cannulas, switches,
and connectors. The two CPB systems under investigation
had the following characteristics:
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1. In the Duraflo II circuit, all surfaces in contact with
blood were coated with a water-insoluble heparin
complex. The circuit consisted of silicone and
polyvinyl chloride tubings connected to a hard-shell
cardiotomy reservoir (DII BCR-3500 Gold); a soft-
shell venous reservoir (DII BMR-1900 Gold); a
woven, hollow, polypropylene fiber membrane oxy-
genator (Spiral Gold; surface area, 1.90 m2); and a 25-
µm arterial filter (DII AF-1025 Gold).
2. In the CBAS circuit every part of the extracorporeal
equipment was coated with end-attached covalent-
bonded heparin. The circuit included polyvinylchlo-
ride tubings connected to a hard-shell cardiotomy
reservoir (CB 1351); a collapsible venous reservoir
bag (CB MVR 1600); a woven, hollow, polypropylene
fiber membrane oxygenator (CBMAXPRF; surface
area, 2.30 m2); and a 20-µm arterial filter (CB M-20).
The extracorporeal circulation was performed with the use
of a Stöckert roller pump with a pulsatile flow control (PFC
III; Stöckert Instrumente GmbH, Munich, Germany). In both
groups the sizes of the aortic and the 2-stage venous cannu-
las were 22F and 48F, respectively. A cardiotomy suction line
was available for both systems and was frequently used dur-
ing CPB. The circuits were primed with Ringer’s acetate,
approximately 2000 mL for the Duraflo II circuit and 2300
mL for the CBAS equipment. Mild hypothermia (blood tem-
perature, 32°C) was instituted immediately after the start of
bypass. Each circuit was examined visually for evidence of
clots or fibrin formation after termination of CPB. 
A reduced dose of heparin (Nyco Pharma, Asker, Norway),
100 IU/kg, was used for anticoagulation. The activated clot-
ting time (ACT; HemoTec, Englewood, Colo) had to exceed
250 seconds before CPB was started, and supplemental doses
were administered if necessary to maintain this target ACT.
ACT was repeatedly determined during CPB, after protamine
administration, and 2 hours postoperatively. For neutraliza-
tion of heparin, a bolus dose of protamine (protamine sulfate;
Novo Nordisk, Bagsvard, Denmark), 1.3 mg/100 IU heparin,
was given. The extracorporeal bypass was disconnected
before the administration of protamine sulfate. An additional
protamine dose was considered if postoperative bleeding was
more than 1.5 to 2 mL/kg body weight during the first 2 post-
operative hours, if ACT was more than 140 seconds, or both.
Postoperative arrhythmias. After continuous registration
of the electrocardiogram during the day of the operation, all
patients were monitored with continuous telemetry for 48
hours. In cases of arrhythmias, telemetry was prolonged or
reinstituted. All patients having one or more episodes of
arrhythmias were prospectively registered. Preoperative med-
ication (β-blockers, Ca++-channel blockers, and digitalis) was
continued from the first day after the operation. In those
patients not receiving β-blockers preoperatively, such treat-
ment was instituted at the first postoperative day. 
Statistical analysis. Comparison of the 2 groups was done
by the Mann-Whitney U test for continuous variables.
Discrete variables were treated by means of contingency
tables with the Yates correction, and the Fisher test was per-
formed when one of the expected cell values was less than 5.
The data are presented as means ± SD. All data were record-
ed prospectively and stored in a database.
Table I.  Demographic data and operative details of the Duraflo II group and the CBAS group
Clinical parameters Duraflo II group (n = 675) CBAS group (n = 661) P value
Age (y) 63.9 ± 9.5 64.0 ± 9.6 .78
Female sex (%) 20.9 18.0 .21
Weight (kg) 80.6 ± 17.0 81.9 ± 17.3 .08
Emergency operation (% of patients) 9.0 9.1 .76
Redo operation (% of patients) 1.8 2.7 .24
Ejection fraction 0.67 ± 0.14 0.67 ± 0.14 .86
Left main stenosis (% of patients) 25.2 25.9 .76
Previous myocardial infarction (%) 51.4 48.4 .27
Blood cardioplegia (high-risk patients; %) 36.3 38.9 .35
No. of distal anastomoses 4.6 ± 1.3 4.6 ± 1.3 .67
Ischemic time (min) 34.9 ± 10.4 35.6 ± 10.9 .35
Extracorporeal time (min) 56.6 ± 15.4 57.0 ± 15.4 .36
Spontaneous sinus rhythm after declamping (%) 88.6 85.3 .07
Values are given as mean ± SD where shown. There were no statistically significant differences between the groups.
Table II. Heparin and protamine sulfate doses given to the Duraflo II group and the CBAS group
Duraflo II group (n = 675) CBAS group (n = 661) P value
Pre-CPB heparin (IU) 9,507 ± 2,245 10,182 ± 2,628 <.0001
Supplemental heparin during CPB (IU) 732 ± 1517 3,174 ± 2,545 <.0001
Protamine sulphate after CPB (mg) 128.3 ± 28.5 136.9 ± 34.1 <.0001
Supplemental protamine sulphate in ICU (mg) 29.8 ± 16.7 (n = 109) 29.3 ± 9.8 (n = 91) .51
Values are given as mean ± SD where shown. ICU, Intensive care unit.
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Results
The demographic data are listed in Table I. The slight
difference in number of patients in the 2 groups was
due to a short period of delayed supply of equipment
from one manufacturer. Otherwise, no significant dif-
ferences were observed for any parameters. Operative
characteristics, such as the number of distal anasto-
moses, aortic crossclamping times, and extracorporeal
times, were similar, as was the distribution of high-risk
patients (given blood cardioplegia). Sinus rhythm
returned spontaneously after declamping of the aorta at
equal proportion in the 2 groups.
Heparin was given at lower initial amounts in the
Duraflo II group because the experience of heparin
leakage from this surface gradually became evident
during the investigation period (Table II). Even more
pronounced was the much lower rate of supplemental
heparin doses (23.3% of the patients) that were
required in the Duraflo II group compared with those
required in the CBAS group (75.3% of the patients; 
P < .0001) to maintain the lower limit of the ACT.
Despite this fact, the ACTs during CPB were signifi-
cantly higher in the Duraflo II group (P < .001, Fig 1).
The protamine dose was given in the amount of 1.3
mg/100 IU initial heparin dose and was accordingly
somewhat higher in the CBAS group. There were no
significant intergroup differences in the postoperative
ACTs, and the amount of extra protamine given post-
operatively was similar in both groups. No technical
problems were recorded during CPB. In the CBAS
Fig 1.  Despite lower doses of heparin given to the Duraflo II group, the ACT on CPB was significantly higher than
that found in the CBAS group (*P < .001). This is probably due to leakage of heparin from the Duraflo II surface
to the circulation. Values are given as means ± SD.
Table III.  Clinical end points in the Duraflo II and CBAS groups
Clinical end points Duraflo II group (n = 675) CBAS group (n = 661) P value
Fluid excess at ICU arrival (mL) 3145 ± 777 3420 ± 882 .001
Fluid excess during first 18 h postop (mL) 2203 ± 860 2387 ± 899 .26
Serum creatinine-maximal postop increase (µmol/L) 7.5 ± 30.3 5.4 ± 16.4 .06
Ventilatory support postop (h) 1.7 ± 1.3 1.6 ± 1.0 .37
Postoperative AF (preoperative AF excluded; % of patients) 26.4 27.9 .54
Perioperative myocardial infarction (% of patients) 1.5 1.5 .96
Walking stairs outdoors before postop day 5 (% of patients) 93.0 92.1 .15
Stroke (% of patients) 1.3 1.2 .47
Minor neurologic events (% of patients) 0.6 0.5 .26
Mediastinitis (% of patients) 0.4 0.8 .35
Hospital mortality (% of patients) 0.14 0.45 .31
Values are given as mean ± SD where shown. ICU, Intensive care unit; postop, postoperative; AF, atrial fibrillation.
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group some clots were seen in the cardiotomy reser-
voirs after the operation in 2 patients having redo oper-
ations, but no clinical consequences were recorded.
The lowest ACTs during CPB in these patients were
310 seconds and 271 seconds, respectively.
The clinical outcome variables are shown in Table
III. An excess of fluid at the end of the operation was
significantly higher in the CBAS group in accordance
with the higher priming volume required for this cir-
cuit. This difference disappeared after 18 hours. For all
other variables, no statistically significant differences
between the groups were demonstrated. The patients
were extubated early in both groups, and the incidence
of new episodes of atrial fibrillation and the rate of
perioperative myocardial infarction were similar. No
differences were seen regarding renal function, inci-
dence of neurologic complications, or progress of
physical rehabilitation. There was 1 (0.14%) hospital
death in the Duraflo II group and 3 (0.45%) deaths in
the CBAS group (P = .31).
Because of the leakage of heparin in the Duraflo II
group, this instability of the surface could potentially
be of importance in cases of prolonged CPB.
Therefore, a separate analysis was done for patients
having a CPB time of more than 60 minutes. In the
CBAS group 229 patients had a CPB time of 73.3 ±
12.1 minutes, and in the Duraflo group 212 patients
were perfused in 73.3 ± 14.7 minutes (P = .30). No sig-
nificant differences were seen in any of the variables
outlined in Table II and Table IV, except for the similar
differences in fluid balance, which was shown for the
entire group.
Discussion
Several studies have demonstrated that the use of
heparin-coated circuits for CPB attenuates the activa-
tion of the immunologic system, the white blood cells,
and the endothelial cells.1,4,14-16 These indications of
reduced postperfusion inflammatory response have
been shown to be more pronounced for the CBAS than
for the Duraflo II surface.14-16 Both the C3 activation
products C3b, iC3b, and C3c (C3bc) and the terminal
SC5b-9 complement complex were significantly lower
during CPB with the CBAS equipment compared with
CPB with the Duraflo II system.14 Similarly, the same
effects were seen for the granulocyte activation
enzymes lactoferrin and myeloperoxidase,15 as well as
for the release of endothelin 1.16 We hypothesized that
the disparity in affecting biologic markers could even-
tually lead to corresponding clinical consequences,
particularly regarding lung and kidney function, as well
as postoperative bleeding and need for blood transfu-
sions. However, in the present study there was a strik-
ing similarity of all major clinical end points in the 2
groups. The only difference in routine clinical use was
the reduced need for heparin to maintain the target
ACT during CPB in the Duraflo II group. This has been
demonstrated both experimentally13 and in clinical
studies14 and is assumed to be due to leakage of heparin
to the circulation from the Duraflo II surface. In vitro
recirculation loop tests of coated arterial filters13 have
shown that about 10% of the bonded heparin was cir-
culating shortly after fluid exposure but remained sta-
ble at this level for 2 hours. This instability of the
Duraflo II surface could theoretically be of importance
in cases with prolonged time of extracorporeal circula-
tion. However, we were not able to demonstrate any
intergroup differences when comparing the subpopula-
tions of patients having a CPB time of more than 60
minutes. From a practical point of view, more attention
has to be kept on monitoring the ACT during CPB with
the CBAS system because more supplemental heparin
is likely to be given. In this context it should be empha-
sized that duplicate ACT measurements are necessary
because of considerable variability in single determina-
tions.18 Despite the different ACTs during the opera-
Table IV.  Postoperative data for the Duraflo II and CBAS groups
Postoperative data Duraflo II group (n = 675) CBAS group (n = 661) P value
Mediastinal drainage 18 h postoperatively (mL) 665 ± 257 688 ± 270 .07
Autotransfusion of shed blood (mL) 631 ± 249 651 ± 243 .05
Resternotomy for bleeding (% of patients) 1.6 2.0 .64
Red cells (± plasma) transfusions (% of patients) 3.3 3.3 .93
Plasma transfusion (% of patients) 0.9 1.1 .96
Platelets preoperatively (×103) 211 ± 53 207 ± 55 .20
Platelets at discharge (×103) 227 ± 73 223 ± 68 .29
Hemoglobin concentration preoperatively (g/L) 142 ± 12 141 ± 12 .31
Hemoglobin concentration at discharge (g/L) 120 ± 13 119 ± 13 .08
Values are given as mean ± SD where shown.
tion, the doses of protamine administered after CPB
were calculated similarly in both groups (1.3 mg of
protamine-sulphate/100 IU of heparin given before
CPB) and worked out well because the need for addi-
tional protamine doses was nearly identical for both the
Duraflo II and CBAS group.
The less-thrombogenic surfaces of heparin-coated
circuits have allowed a reduced dose of heparin for sys-
temic anticoagulation during CPB. This combination
has been shown to be safe and blood saving in previous
randomized clinical studies.7-10 Aldea and colleagues8
were able to demonstrate less bleeding and less need
for allogeneic transfusions, and this was proved in a
later study19 to be an effect of a reduced anticoagula-
tion protocol with an ACT of greater than 250 seconds.
They also experienced a shorter intubation time, fewer
postoperative complications, and shorter intensive care
unit and hospital stays. Svenmarker and colleagues10
demonstrated signs of improved cerebral protection
with CBAS-coated CPB and reduced heparin dose.
These previous clinical results were clearly confirmed
in the present study, which included a much larger
number of patients than the studies mentioned. The
intubation times were short, and the overall complica-
tion and mortality rates were favorable in both groups.
The postoperative bleeding was moderate, and we were
able to avoid allogeneic transfusions in more than 95%
of the patients. A main surgical experience was an
impression of a dry operation field shortly after admin-
istration of protamine, which made the hemostasis and
the whole operation less time consuming.
The effects of reduced heparin dose on postoperative
bleeding is not unexpected because heparin itself is
known to induce fibrinolysis and platelet dysfunction
even before CPB.20 The fear of increased thrombin for-
mation and even intravascular thrombosis when reduc-
ing systemic heparin could not be confirmed in a pre-
vious study comparing a full heparin dose (ACT > 480
seconds) with a low heparin dose (ACT > 250 seconds)
along with heparinized CPB circuits.21 Technical prob-
lems with obstruction of the extracorporeal circuits
have thus far not been recorded. Nevertheless, having
recorded some clots in the cardiotomy reservoir after
CPB in 2 redo patients, we now use a full heparin dose
in this subgroup of patients. It might be suggested that
in redo patients more tissue factor is released after
extended dissection of scar tissue, and this may subse-
quently initiate local coagulation.
An additional advantage of reducing the intravenous-
ly delivered dose of heparin is the reduced need for
protamine because protamine is known to cause hemo-
dynamic instability, hypersensitivity, and complement
The Journal of Thoracic and
Cardiovascular Surgery
Volume 121, Number 2
Øvrum et al 329
activation.22 In particular, heparin-coated circuits and
reduced systemic levels of heparin represent an alter-
native option for patients known to react adversely to
protamine.
Clinical studies of heparin-coated CPB circuits with
full systemic heparinization have thus far not been able
to demonstrate any effects on postoperative bleeding or
rate of transfusions. Two multicenter studies compar-
ing Duraflo II and uncoated controls with an ACT of
greater than 480 seconds in both groups have been pub-
lished.23,24 In the European study,23 enrolling 805 low-
risk coronary patients, no clinical benefits were seen
considering postoperative bleeding, transfusion
requirements, intubation times, or recovery for the
whole population. In analyses of patient subpopula-
tions, female patients receiving heparin-coated circuits
had less transfusions and were extubated earlier than
the control subjects. For the subgroup of patients hav-
ing an aortic crossclamp time greater than 60 minutes,
a shorter intensive care treatment was recorded. A sim-
ilar pattern was demonstrated in an Italian multicenter
study,24 also using full heparinization in a high-risk
series of 886 patients. There were no overall differ-
ences in bleeding or transfusions. However, the use of
heparin-coated equipment was associated with a short-
er intensive care unit and hospital stay and with a lower
number of patients with a severely impaired clinical
outcome.
A separate benefit for using heparin-coated circuits is
reduced incidence of postoperative atrial fibrillation. In
a prospectively randomized study, we reported a
reduced rate of atrial fibrillation using Duraflo II–coat-
ed circuits (and full heparin dose) compared with iden-
tical uncoated controls.25 The overall incidence of new
episodes of atrial fibrillation fell from 43.1% to 21.8%
and was even more pronounced in the younger patients.
The rate of postoperative atrial fibrillation was some-
what higher in the present study (27%) and was proba-
bly due to a continuous increase in the number of elder-
ly patients year by year. In the European multicenter
study,23 similar beneficial influence on postoperative
supraventricular arrhythmias was seen in female
patients.
The reason for the absence of any disparities in clin-
ical end points between the two heparinized surfaces,
despite having different influences on inflammatory
markers, remains unclear. It might be assumed that the
total effects on the biologic cascades for both systems
are too small to show any significant improvement of
organ function during and after CPB. The present clin-
ical end points may also be too insensitive; however,
the clinical performance and postoperative recovery is
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of ultimate interest when investigating new technolo-
gies used for treatment of patients.
In summary, no significant differences in clinical per-
formance were seen comparing the CBAS equipment
with the Duraflo II–coated system during and after
coronary artery bypass operations. The CBAS technol-
ogy is more complex and consequently more expensive
than the Duraflo II system. This fact may be of rele-
vance, at least when considering a routine use of
heparin-coated circuits for extracorporeal circulation.
On the other hand, the CBAS appears more stable than
the Duraflo II surface, and this may have some effect in
more critically ill patients, in whom a longer extracor-
poreal time is necessary.
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